ArticleFrontiers in microbiology2022
Evaluation of three rapid low-resource molecular tests for Nipah virus.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Assessing the pandemic potential of Nipah virus: From molecular pathogenesis to ecological spillover risks.Infectious medicine · 2026Review
- Nipah Virus: A Neurotropic Zoonosis-From Molecular Biology to Clinical Manifestations and Translational Advances.Viruses · 2026Review
- Development and analytical validation of a dual-gene isothermal assay for Nipah virus detection.Applied microbiology and biotechnology · 2026Article
- Nipah virus molecular detection from whole blood and respiratory swabs in a rapid field-ready protocol.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2026Article
- Review
- Nipah virus infection: what clinicians need to know.Le infezioni in medicina · 2026Review
- Emerging Vector-Borne Nipah Virus Infection: Unexplored Hazards, Diagnostic Challenges, and the Potential of Phytomedicine-Based Therapeutics.Current pharmaceutical design · 2026Review
- Strengthening preparedness and response to emerging henipavirus diversity.Frontiers in cellular and infection microbiology · 2026Review
- Development and proof-of-concept evaluation for a low resource compatible Chikungunya virus diagnostic.PLoS neglected tropical diseases · 2025Article
- Review
- Laboratory Diagnosis of Hendra and Nipah: Two Emerging Zoonotic Diseases with One Health Significance.Viruses · 2025Review
- Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics.Clinical microbiology reviews · 2025Review
- Advancements and Challenges in Addressing Zoonotic Viral Infections with Epidemic and Pandemic Threats.Viruses · 2025Review
- A Stable and Dependable Visual Technique for On-Site Nipah Virus Nucleic Acids Detection.Scientific reports · 2025Article
- Development of a non-infectious control for viral hemorrhagic fever PCR assays.PLoS neglected tropical diseases · 2024Article
- Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries.Viruses · 2023Review
- Rapid, sensitive, and specific, low-resource molecular detection of Hendra virus.One health (Amsterdam, Netherlands) · 2023Article
- Rapid inactivation and sample preparation for SARS-CoV-2 PCR-based diagnostics using TNA-Cifer Reagent E.Frontiers in microbiology · 2023Article
- Development and pre-clinical evaluation of a Zika virus diagnostic for low resource settings.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and timely diagnosis of Nipah virus (NiV) requires rapid, inexpensive, and robust diagnostic tests to control spread of disease. Current state of the art technologies are slow and require laboratory infrastructure that may not be available in all endemic settings. Here we report the development and comparison of three rapid NiV molecular diagnostic tests based on reverse transcription recombinase-based isothermal amplification coupled with lateral flow detection. These tests include a simple and fast one-step sample processing step that inactivates the BSL-4 pathogen, enabling safe testing without the need for multi-step RNA purification. The rapid NiV tests targeted the Nucleocapsid protein (N) gene with analytical sensitivity down to 1,000 copies/μL for synthetic NiV RNA and did not cross-react with RNA of other flaviviruses or Chikungunya virus, which can clinically present with similar febrile symptoms. Two tests detected 50,000-100,000 TCID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.